Canopy Growth enters the UK

Source: Canopy Growth

Spectrum Biomedical UK (Spectrum UK) is a newly formed company focused on providing access of cannabis-based medicinal products to UK patients with severe clinical unmet need. The joint venture between Canopy Growth Corporation (Canopy Growth) (TSX: WEED) (NYSE: CGC) and Beckley Canopy Therapeutics (Beckley Canopy) will be the exclusive distributor of Spectrum Cannabis medicinal products in the UK market.

“We are witnessing the birth of the UK medical cannabis industry, an industry borne out of the unmet clinical needs of patients across the country. The formation of Spectrum UK is testament to the importance of the opportunity to help patients access the medicine here in the UK,” said Marc Wayne, Co-Managing Director, Spectrum Biomedical UK.

“There is significant real world and clinical evidence supporting the safety and effectiveness of cannabis-based medicinal products. However, due to the current regulations and lack of education about medicinal cannabis among clinicians in the UK, there remain considerable obstacles to patient access. Spectrum UK has the expertise and ambition to simplify the UK medicinal cannabis landscape and ensure access to cannabis-based medicinal products for patients with great clinical unmet need,” said Dr Mark Ware, Chief Medical Officer, Canopy Growth.

Spectrum UK will distribute a full range of Spectrum Cannabis products. Spectrum Cannabis products use an industry-first strain classification system, designed to simplify dialogue around strength, dosage, and THC:CBD ratios of medicinal cannabis using a straightforward colour-coded guide. The portfolio includes whole flower cannabis, oils and new innovations such as softgel capsules. There are currently over 80,000 patients being treated with Spectrum Cannabis products worldwide with Spectrum UK aiming to have products available for patients in the UK early 2019.

Leave a Reply

%d bloggers like this: